Emi-Le Demonstrates Promising Activity in Aggressive Adenoid Cystic Carcinoma
Clinical Summary:
-
Design/Population: Analysis of emiltatug ledadotin (Emi-Le; XMT-1660), a B7-H4-directed antibody-drug conjugate, in patients with aggressive adenoid cystic carcinoma, a rare malignancy associated with limited treatment options and poor outcomes.
- Key Outcomes: Among 25 evaluable patients with ACC, Emi-Le achieved an objective response rate of 40% and a disease control rate of 76%. Median progression-free survival and overall survival had not yet been reached at the time of analysis. Across 221 treated patients, the safety profile was generally favorable, with low treatment discontinuation rates and no treatment-related deaths reported.
- Clinical Relevance: These findings suggest that Emi-Le may represent a promising new therapeutic option and support continued clinical development of this B7-H4-targeted antibody-drug conjugate.
Glenn Hanna, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, presents data evaluating emiltatug ledadotin (Emi-Le; XMT-1660), a B7-H4-directed antibody-drug conjugate, in patients with aggressive adenoid cystic carcinoma (ACC), a rare cancer with limited treatment options and poor outcomes.
Among 25 evaluable patients with ACC, Emi-Le achieved a 40% objective response rate and a 76% disease control rate, with median progression-free and overall survival not yet reached at the time of analysis, while demonstrating a generally favorable safety profile across 221 treated patients, with low discontinuation rates and no treatment-related deaths.
These findings highlight the potential of Emi-Le as a promising new therapy for patients with aggressive ACC and support its continued clinical development. Dr Hanna presented these findings at the 2026 ASCO Annual Meeting in Chicago, Illinois.
Source:
Hanna GJ, Rabinowits G, Attarian S, et al. Emiltatug ledadotin (Emi-Le), a B7-H4–directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis. Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. Abstract 6010.
